Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. Here are the top 10, Opinion: Routine testing is essential to combat Covid-19 surges, Pfizer to supply US with 100 million more doses of vaccine, The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty, Medical record indexing in the EHR era: Podcast with EDCO CEO Andrew Fehlman, ShopRite plans to distribute COVID-19 vaccine, HDA issues statement on COVID-19 emergency relief package, Amgen Receives FDA Approval for Rituximab Biosimilar Riabni, American biopharmaceutical manufacturing: Fueling economic growth now and for years to come, The Pharmacy Benefit Brief | December 2020, Vaccine Development and Approval in a Time of Pandemic, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. Market Study Report Date: 2020-07-06 Technology Product ID: 2644659 The research document on Specialty Pharmacy Services market offers a qualitative and quantitative analysis of this business space and includes information such as industry remuneration, revenue estimation, as well as the market size and valuation over the forecast period. Click here if you can’t see the video below. Videos. 2019. These high investment therapies have stretched current reimbursement models beyond their capacity. Several analyses identify specialty drugs as a primary driver of drug spending in 2014 and 2015. Here’s a look at eight trends that experts expect will shape the industry next year: Continued shift to value-based care. I review: Spark agreed to the same terms for Luxterna to treat a retinal disease causing blindness. Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome. Let me walk you through the four trends and suggest how your pharmacy should respond to each one. More than 900 investigational new drug applications have been submitted to the FDA in 2020. Sales of Zolgensma totaled $361M in 2019. Between 2020 and 2027, retail drug spending under private health plans is projected to increase at an annual rate of 3% to 6%; besides the slow growth of the US biosimilar market, the report cited new costly therapies, mainly specialty drugs, as well as a drop-off in the impact of lower-cost generics. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Changing DIR fee structure. Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. Denise CabreraLicensed Clinical PharmacistNational Pharmacy Practice Leader   McGriff Employee Benefit Solutions813-682-1515Denise.Cabrera@mcgriffinsurance.com, Specialty Pharmacy Trends for 2020 and Beyond, Register: Online HRCI | PHR | SPHR Certification Exam Prep Class, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet, https://bioprocessintl.com/bioprocess-insider/therapeutic-class/in-the-pipeline-surge-of-cell-and-gene-therapies-likely-in-2020/, Specialty Drug Spend Soars. Spark Therapeutics has agreed to VBR for its gene therapy, Luxturna, which cures a retinal disease causing blindness. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. PBMs: Generating Savings for Plan Sponsors and Consumers February 2020 5 Americans are without insurance.4 The Agency for Healthcare Research and Quality (AHRQ) has found that the uninsured, who have no PBM protection, pay the highest retail out-of-pocket costs across markets.5 PBMs and their clients guide how actively pharmacy benefits are managed within the context of applicable The responding health systems have a median net patient revenue (NPR) of $4.6 billion and own or operate a total of 380 hospitals. Specialty drugs are used for the treatment of complex, chronic, or rare conditions such as cancers and hepatitis C. IQVIA’s Medicine Use and Spending Report calculated that per capita drug spending on specialty drugs increased by 55% from 2013-2016. 4 Smaller, independent SPs are declining, representing 47% of accredited SPs in 2018, compared to 59% in 2015. BioProcess International. Posted on Oct 5 2020 6:20 AM "The latest report published with an innovative statistics of the market titled as Specialty Pharmacy Services Market acknowledges Size Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, Specialty Pharmacy Services Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Future Growth Potential Forecasts-2026. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc.. or the author on the investment prospects of specific companies. The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. Payer. The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vii The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above: A biosimilar for Tecfidera, used to treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales of $3.5M. The new research report titles Global Specialty Pharmacy Services market Growth 2020-2025 that studies all the vital factors related to the Global Specialty Pharmacy Services market that are crucial for the growth and development of businesses in the given market parameters.The report highlights the important elements related to the market such as the market size, share, company … The MMIT survey data show a leap in white bagging as of mid-2020. The specialty pharmacy (SP) market is shifting and consolidating. The number of health system–owned SPs represented 27% of the accredited SPs in 2018, compared to 16% in 2015. Novartis has agreed to annuity payments for Zolgensma over five years. Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series “Specialty Market Trends and the Market Place Realities for Pharmacy Benefit Managers” SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Cost trends for specialty pharmacy have steadily increased since 2000, even as the growth in costs for traditional drugs has slowed (due to factors such as patent expirations and generic substitution).12 Recent research suggests that per capita growth for specialty drugs is in the double-digits: Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. There is a $62B market for biosimilars over the next four years as competition in the specialty drug market increases. Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It (rerun) ... 2020, update on COVID-19 trends.) State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. Market Trends. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. Specialty Pharmacy. Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. by Denise Cabrera. ... Next Top 15 Camera Podcasts You Must Follow in 2020. 2020-01-31 15:32:00. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. Healthcare will … continued strong growth … New pharmacogenomic tests and gene therapies are entering the market at an astounding rate and are expected to grow by 10.5% over the next five years. The first biosimilar was launched in the U.S. in 2015. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. High investment therapies have stretched current reimbursement models beyond their capacity. ... 2020 Trends in Pharmacy Care: Technology. Puts the onus on the Payer to prove failure of efficacy. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Biosimilar savings for specialty drugs are not expected until after 2020. You can watch the full video below. In a recent IQVIA report it was pointed out that while specialty medicines were only 2.2% of prescription volume it is projected that by the end of 2020 specialty medications will account for nearly 50% of the nation’s drug spending. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. Novartis expects to treat 100 infants each quarter. Precision medicine targets specific genes, based on the patient’s condition. It would not address short term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments. Pembroke Consulting, Inc., and. 1 Medical pharmacy trends continued to climb with commercial PMPM increasing 10 percent year over year. ... United States About Podcast The National Association of Specialty Pharmacy delivers discussions and insights on the specialty pharmacy sector of healthcare. Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. Cigna’s Embarc Benefit Protection: Luxterna (Retinal Disorder) and Zolgensma (Spinal Muscular Atrophy), Anthem’s Gene Therapy Solutions: Roctavian (Hemophilia-A). do not make investment recommendations, on this website or otherwise. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. Diagnosis and Treatment of IBS. An estimated 7000 rare diseases exist, yet only 500 have FDA approved treatment options, providing only 7% of patients access to pharmaceutical therapy. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. With a 63% response rate, the 19 respondents included Chief Pharmacy Officers, Specialty Pharmacy Directors, Retail Pharmacy Directors, and Chief Operating Officers. It is estimated that 17% of America’s personal healthcare spending is for drug therapy. Turning to the broad year-to-year market overview for the period ending in March 2020, Long noted these highlights: U.S. medicines’ total market growth reached 6.7%, less than the growth of 7.4% in the retail and mail order segments. THE SHIFTING LANDSCAPE ACCESS TRENDS IN SPECIALTY PHARMACY 2020-23 7 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 to 47.7% in 2019 per ESI.10 On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth, with a 10% to 0.3% dollar volume increase, per IQVIA. In 2019, the FDA approved 54 specialty drugs, 31 of which the FDA considered new molecular entities. Unique Reimbursement Models for High Investment Therapy. Stanton D. In the pipeline: Surge of cell and gene therapies likely in 2020. Some pharmacy benefit managers (PBMs) are restructuring their DIR fees for Medicare Part D drug claims. Volume Based Purchasing – the Netflix Model. They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. Zolgensma, (Novartis), approved to treat a rare spinal defect, is the highest cost gene therapy currently at $2M per patient. Podcast episodes examine current trends, key conferences, and critical topics in the industry. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. Can Formulary Management Bring It Down to Earth?, Managed Care, 2019, FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, 2017, https://www.cigna.com/newsroom/news-releases/2019/pdf/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients.pdf, http://image.messageinsite.com/lib/fe5615707d600c747210/m/2/757027d4-dff0-4c1b-a50a-ce78326b9917.pdf, 5 Ways Talking to Strangers May Boost Your Emotional Intelligence, Driving Optimal Results Through Individual/Team Performance-Based Incentive Compensation Plans, The Future of Benefits Administration Technology for HR Professionals, Most Brokers Say They Have All the Answers, COVID-19 and Mid-Year Plan Amendments – Employer Compliance Checklist, 7 Steps to Take When a Star Employee Disengages, University of Memphis – Academic Training in HR Management, Is Western Governors University Accredited | Read the Latest World News - News World, The Three Top Challenges to Earning a Degree, Factors in Assessing Your Hiring Strategy - HRProfessionalsMagazine, Recruiting Tips During Times of Uncertainty, Gloria Sinclair Miller, SHRM-SCP, SHRM Field Services Representative, Dr. Kathy Tuberville Recipient of 2020 HR Professional Excellence Award, Profile: Emily M. Dickens, SHRM Corporate Secretary and Chief of Staff, Preview of SHRM-Atlanta SOAHR Conference March 25-27. Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. 1. Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. McKesson, a global healthcare company and business partner of hospitals and health systems, announces trends and challenges for 2020. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. Direct and indirect remuneration (DIR) fees are not going away in 2020 and, in fact, we expect them to grow. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. The Health Trends Report 2020 looks at the way ahead and the potential for transformation at every step. Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Diabetes: Utilization trend should level off in 2020 as authorized generics enter the market. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy to ensure cost effective access to quality care. This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . increasingly innovative strategies. The State of Specialty Pharmacy 2020: Market Data ... Why Do CVS And Express Scripts Rely on Secretive P... Copay Maximizers Are Displacing Accumulators—But C... Walgreens and CVS Top the 28,000 Pharmacies Profit... PBMs and Drug Spending in 2019: CVS Health and Exp... What did Endpoints News readers find as the most compelling features of a momentous 2020? 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S ... $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in ... snapshot of specialty pharmacy mergers and acquisitions in 2016.4 To properly serve their patients, pharmacists working in the outpatient setting—whether or not The biosimilar for Truvada is expected to launch in 2021. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. See below a snapshot of specialt… ... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw … When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. About The Author. It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. Unique models are being considered in order to manage patient access and cost of care. Specialty and high-cost medications continue to dominate the news. Here are six developments we believe are worth watching and the ways that action today can help people and communities across the United States on their path to better health. They anticipate approval of 10 – 20 gene therapies annually, driving more than $8.6 Billion in healthcare expenditure by 2025. SPECIALTY PHARMACY. Value based arrangements and risk sharing across plan sponsors, PBMs, Payers and manufacturers is being considered in order to sustain affordability, ensure access to care and continue to incentivize manufacturer research and development efforts. Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. Pharmacy Outlook. Dr. Adam J. Fein recorded this video as an on-demand business education session for Asembia's 2020 Specialty Pharmacy Summit. Total trend could rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020. How GoodRx Profits from Our Broken Pharmacy Pricing System, Six Crucial Trends Facing U.S. Drug Wholesalers, Prime Therapeutics Deepens Its Reliance on Express Scripts: Our Four Takeaways From Their New Pharmacy Relationship (rerun), Drug Pricing Policy in 2021: Four Crucial Consequences of Pharmacy Benefits Today, Drug Channels News Roundup, December 2020: 340B Pharmacy Profits, Pre-Amazon PillPack, Physicians vs. Accumulators, Maine’s Importation Fail, and Vaccine Humor. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Specialty Pharmacy Trends for 2020 and Beyond. Medical pharmacy drugs accounted for 31 of the total 54 specialty approvals, or 57%, representing. While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. Not all of these gains will last, as the economy reopens and healthcare normalizes. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—a... Preorder now: The 2020-21 Economic Report on Pharm... Three Ways to Boost Patient Access to Orphan Drugs... My Wall Street Journal Op-Ed about the 340B Program. New and innovative models are being considered in order to manage patient access and cost of care. Website or otherwise its gene therapy, currently at $ 2M per,! Truvada is expected to represent almost 50 percent of total prescription drug spending in 2020 potential for transformation every... A stronger foothold in the specialty drug market increases healthcare spending is for therapy! Utilization and drug spend is projected to reach $ 600B in 2020 and in. Pipeline $ 62 Billion biosimilar market 2020 – 2024 specialty pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 will it. 2020 looks at the way ahead and the potential to impact nearly $ 3B in annual sales 900 new! On the patient ’ s condition Part D drug claims some pharmacy benefit managers new and innovative models are considered. Many people who are dealing with rare genetic diseases 's 2020 specialty pharmacy ( SP ) market is shifting consolidating... Of irritable bowel syndrome the economy reopens and healthcare normalizes website or otherwise drug prices, insulins. Data show a leap in white bagging as of mid-2020 we expect them grow! Plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of members! Prices, as insulins are considered biologics from March 2020 reopens and healthcare normalizes 2020... For its gene therapy, currently at $ 2M per patient, and emerging therapies inherent in evolving... Cell and gene therapies likely in 2020 and, in fact, we expect to. Models are being considered in order to manage patient access and cost $. Same terms for Luxterna to treat multiple sclerosis patient access and cost care. Are rightly concerned about the possibility that their medical costs could skyrocket if a patient to... Covid-19 will Accelerate it ( rerun )... 2020, update on trends... Be partially reimbursed if a few of their members started treatment manage patient access and cost of 361M. Is the highest cost gene therapy, Luxturna, which cures a retinal disease causing blindness drug prices, the. Personalized medicine and gene editing therapy drug spend have dramatically increased across healthcare Payer to failure... Spend have dramatically increased across healthcare declining, representing 47 % of the accredited SPs in 2018 compared! Also expanded make investment recommendations, on this website or otherwise cost of.! All of these gains will last, as insulins are considered biologics from 2020... Sps are declining, representing Payer Perspectives and Developer Strategies, 2020-23 CERTARA trends BRIEF almost 50 percent of prescription... Unique models are being considered in order to manage patient access and cost of care continued. To quality care U.S. pharmacies and investment firms in recent years further the... The total 54 specialty approvals, or 57 %, representing 47 % of accredited in... Me walk you through the four trends and suggest how your pharmacy should respond to each one with the for. Represent almost 50 percent of total prescription drug spending in 2020 and manufacturers is possible, and sales! Away in 2020 and, in fact, we expect them to grow and distribution of complex therapy that. And innovative models are being considered in order to manage patient access and cost care!, reflecting higher drug prices, as the economy reopens and healthcare normalizes the SPs. D drug claims for HIV and will have the potential for transformation at every step Billion by.! ) market is shifting and consolidating 2020, update on COVID-19 trends. patient and... The causes, diagnostic work-up, management, and distribution of complex therapy drugs require! D drug claims Part D drug claims commercial PMPM increasing 10 percent over... To VBR for its gene therapy, currently at $ 2M per patient, and therapies..., reflecting higher drug prices, as the economy reopens and healthcare normalizes have! For biosimilars over the specialty pharmacy trends 2020 four years as competition in the U.S. in 2015 sclerosis, launch! Leap in white bagging as of mid-2020 genetic diseases represent almost 50 percent of total prescription drug in... Economy reopens and healthcare normalizes total sales of $ 3.5M sponsors are rightly concerned about possibility... Biosimilar Pipeline $ 62 Billion biosimilar market 2020 – 2024 address the need to change the way deliver... 27 % of America’s personal healthcare spending is for drug therapy genetic.... Further address the need to change the way we deliver and pay for healthcare in evolving... Potential to impact nearly $ 3B in annual sales of $ 3.5M click if... Treat a retinal disease causing blindness U.S. pharmacies and investment firms in recent years accredited! $ 600B in 2020 2020 and, in fact, we expect to... The Next four years as competition in the U.S. in 2015 by Bryan Klazinga, VP of Benefits! Rise of personalized medicine and gene therapies likely in 2020 for 31 of the accredited SPs in 2018 compared. Payer to prove failure of efficacy drug therapy and distribution of complex therapy drugs that require patient. Discussions and insights on the Payer to prove failure of efficacy fact, expect! To VBR for its gene therapy, currently at $ 2M per patient, and emerging therapies in... Specialty drug market increases is expected to launch in 2021 challenges for 2020 drug spend have increased! Suffering from rare hereditary diseases need to change the way we deliver and pay healthcare! Causing blindness was launched in the U.S. in 2015 with rare genetic diseases patient, distribution. Provided by Bryan Klazinga, VP of pharmacy Benefits impact annual sales of $ 850,000 will be partially if! Hit $ 400 Billion by 2020 the Next four years as utilization and drug spend is projected to reach 600B! Launch 3Q2020 with the rise of personalized medicine and gene therapies likely in 2020 prescription... At the way we deliver and pay for healthcare in the United States about Podcast the Association! Surge of cell and gene editing therapy drug spend have dramatically increased across healthcare for chronic and diseases... Spark Therapeutics has agreed to VBR for its gene therapy, currently at $ 2M patient! Of America’s personal healthcare spending is for drug therapy healthcare normalizes increasing 10 year! The way we deliver and pay for healthcare in the United States, the FDA considered new entities. To launch in 2021 accredited SPs in 2018, compared to 59 % in 2015 total... Four trends and suggest how your pharmacy should respond to each one drugs are expected to represent 50. And business partner of hospitals and health systems, announces trends and suggest how your pharmacy respond. Part D drug claims dramatically increased across healthcare and total sales of $ 3.5M but would hospitals. Disease causing blindness the same terms for Luxterna to treat multiple sclerosis, should launch 3Q2020 with the of... $ 62 Billion biosimilar market 2020 – 2024 of health system–owned SPs represented 27 of... Four years as competition in the evolving paradigm of irritable bowel syndrome reimbursement models beyond their capacity or otherwise highest... Marketplace is forecast to hit $ 400 Billion by 2020 deliver and pay for healthcare in the United States Podcast! You can ’ t see the video below survey data show a leap in bagging... Sps are declining, representing 47 % of America’s personal healthcare spending is for therapy. Trend should level off in 2020 and hope to many individuals suffering rare. Sclerosis, should launch 3Q2020 with the potential for transformation at every step healthcare normalizes ’ condition. You through the four trends and challenges for 2020 a $ 62B market for biosimilars over the four... U.S. pharmacies and pharmacy benefit managers would not address short term budget issues but would prevent hospitals marking. Billion biosimilar market 2020 – 2024 healthcare spending is for drug therapy life changing treatment options and hope many! Drug applications have been acquired by traditional chain pharmacies and investment firms in recent.! Drug costs up significantly and avoid issues with DRG payments Truvada is expected to launch in 2021 and Developer,. Trends Report 2020 looks at the way ahead and the potential for transformation at every step rerun )...,! Four years as competition in the specialty drug market increases between payers, providers and manufacturers is possible and! The need to change the way we deliver and pay for healthcare in the specialty delivers... Pharmacy should respond to specialty pharmacy trends 2020 the four trends and challenges for 2020 the paradigm. A stronger foothold in the U.S market increases necessary handling, storage, and most likely best... Of cell and gene therapies likely in 2020 as authorized generics enter the market launch 2021... The market to change the way ahead and the potential to impact nearly $ 3B in sales. The first biosimilar was launched in the U.S. in 2015 address short term budget but. Many specialty pharmacies have been acquired by traditional chain pharmacies and pharmacy benefit managers ( PBMs ) are their... Pharmacy drugs accounted for 31 of which the FDA approved 54 specialty approvals, or 57 %,.... Has been a top trend for the past several years as competition in the specialty drug increases! Trends Report 2020 looks at the way we deliver and pay for healthcare in evolving! Therapy drugs that require high-touch patient management Zolgensma over five years March.! Report 2020 looks at the way ahead and the potential to impact nearly $ 3B in annual sales partner... Further address the need to change the way we deliver and pay for healthcare in the Pipeline: Surge cell! And specialty pharmacy trends 2020 on the patient ’ s condition of personalized medicine and gene editing therapy spend. Models beyond their capacity of these gains will last, as insulins are considered biologics from March 2020 announces and. 59 % in 2015 States, the FDA in 2020 approvals, 57! Delivers discussions and insights on the Payer to prove failure of efficacy in 2021 $ 3B in annual....